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Abstract  
Background: Lymphatic filariasis (LF) is targeted by WHO for global elimination as a public health problem by 
year2020. GoI is signatory to WHO resolution and envisaged elimination by instituting annual mass drug 
administration (MDA) in all endemic districts under NVBDCP by year 2015.With rapid industrialization and 
urbanization, large number of landless farmer, unskilled/skilled labour migrate either singly or with entire family 
members to other states (which may be non-endemic for LF) in search of employment. These migrants from 
endemic states escape MDA beings migrated to non-endemic states. Aims and Objectives: To find out prevalence 
of LF and MF density among migrant staying in non-endemic states and assess needs to institute MDA in such 
migrants. Material & Methods: This study was a cross sectional epidemiological study carried out in migrant 
population staying at/near the construction site covering the population of 1640. However, only 1092 person 
participated in the study. Result: A total of 1092 people agreed to participate in the study, out of which, 22 were 
found MF positive and 4 presented with clinical signs of LF. The study found MF prevalence of 2.01% with average 
MF density of 3.90. Conclusion: Endemicity (2.01%) of MF among migratory population more than national 
average (0.45%), which is capable of continuing transmission (>1%) in population at risk living in non-endemic 
states where MDA is not administered.  
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Introduction  
Lymphatic filariasis (LF) a debilitating disease is one 
of the most prevalent and yet one of the most 
neglected tropical diseases with serious economic 
and social consequences (1) LF is a vector-borne 
parasitic disease that is endemic in many tropical and 
subtropical countries. The current estimate reveals 
that 120 million people in 83 countries of the world 
are infected with lymphatic filarial parasites, and 
more than 1.1 billion (20% of the world’s population) 
are at risk of acquiring infection. It is one of the 
world’s leading causes of permanent and long term 
disability. 
Over 40 million people are severely disfigured and 
disabled by filariasis and 76 million are apparently 
normal but have hidden internal damage to 
lymphatic and renal systems.(2) In 1977, the 
50thWorld Health Assembly (WHA) resolved that LF 
should be eliminated as a public health problem by 
the year 2020. The Global Programme to Eliminate 
Lymphatic filariasis (GPELF) has been one of the most 
rapidly expanding global health programme in the 
history of the public health. GPELF was launched in 
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2000 with the goal to eliminate LF as a public health 
problem by 2020.(3) 
About 63% of the global population requiring mass 
drug administration (MDA) for LF lives in South-East 
Asia region where there are nine endemic countries. 
India accounts for 69.4% of the total population 
requiring MDA in the region. (4) 
In India, LF is endemic in 250 districts in 20 states and 
UTs. The population of about 600 millions in these 
districts is at risk of LF.(5) The strategy of LF 
elimination is through annual MDA of single dose of 
Diethyl Carbamazine citrate (DEC) + Albendazole for 
a minimum 5 rounds or more to the eligible 
population (except pregnant women, children <2 
years and seriously ill person) to interrupt 
transmission of infection.(6) 
In the State of Punjab sizeable number of migrants 
come from nearby states like UP (0.24 million), Bihar 
(0.14 million) and Haryana (0.11 million).(7) Many of 
these migrants are from the states which are 
endemic for LF. Migration to non-endemic states 
deprives them from MDA administered in endemic 
states for control of LF under NVBDC programme. 
These migrant persons from endemic states if having 
infection of lymphatic filariasis in incubating, 
subclinical or in asymptomatic stage, in absence of 
treatment act as a reservoir and have potential of 
transmission of infection in non-endemic states. 
Several epidemiological and prevalence studies have 
been done by various researchers in endemic states 
on filariasis. However, studies have not been done 
for prevalence of filariasis in migrant population 
living in clusters on temporary basis in non-endemic 
states.  
Aims & Objectives 
To assess prevalence of lymphatic filariasis among 
migrant people living on/near construction projects 
in non- endemic states 
Material and Methods 
This cross sectional epidemiological study was 
carried out in migrant population staying at/near the 
construction site outskirts of Bathinda town in 
Punjab covering the population of 1640. However, 
only 1092 person participated in the study.  
Results 
1640 (1384 males and 256 females) people were 
staying on/near construction projects. However, 
only 1092 (66.58%) agreed to participate in the study 
out of which 922(84.43%) were males and 170 
(15.57%) females. Five participants, all males, were 
found having filariasis on clinical examination, 
whereas 22 (21 males and 1 females) were found 
microfilaria (mf) positive on blood slide. None of 
these mf positive people showed clinical features of 
filariasis. 
The study population belonged to nine states (Six 
endemic and three non-endemic states) and two 
persons were from Nepal. The state wise distribution 
of study population shown in (Table1) 
The socio-demographic profile of study population 
and mf positive person shown in (Table 2) 
Note – 
 41 children below 10 years and 37 children 10-
20 years of age who were not doing any work 
and were excluded in trade wise distribution. 
 Balance of 195 children of 10-20 years of age 
though not formally employed but helping their 
parents on worksite hence considered as 
unskilled worker. 
 Out of 41 children below 10 years, 17 were 
below 6 years and excluded in education wise 
distribution. 
 Balance 24 children of 06-10 yrs (school going 
children) were not attended any formal school 
nor attending at present location hence 
considered illiterate in study. (Table 3) 
 Out of 1092 participants, 1062 (97.25%) 
belonged to the states endemic for LF. Their 
proportion ranged from 
41.21%(Bihar),17.40%(UP),16.85%(MP) to 
0.37% (Chhattisgarh) (Table 1). The age profile of 
study population varied from 06 months to 54 
years with mean age of 29.34 years. Majority of 
study population (69.14%) was young below 30 
years old, illiterate or of primary standard (80.97 
%) and semiskilled/ unskilled (98.35%).22 
(2.01%) people (21 males, 1females) were mf 
positive (prevalence of 2.01 percent). (Table 4) 
The five people were found to have clinical signs 
of LF and none of the clinically diagnosed LF were 
mf positive. The youngest person of mf positive 
was of 06 months and eldest of 47 years with 
average age of 27 years. 86.36% mf positive 
cases were aged below 30 years. All mf positive 
persons were unskilled, semiskilled/skilled. The 
prevalence of mf positive among illiterate and 
primary educated cases was 03.04% and 2.11% 
respectively. 
Information about intake of drugs administered 
under MDA in their native place was also enquired. 
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887(81.24%) did not receive medicine administered 
under MDA in last five years while only 12 (1.09%) 
received medicine thrice or more in last five years. 
(Table 5) 
Discussion  
WHO has targeted lymphatic filariasis global 
elimination and Global Programme to Eliminate 
Lymphatic Filariasis (GPELF) was launched in year 
2000 with the goal to eliminate LF as a public health 
problem by year 2020.The main strategy of GPELF is 
to interrupt transmission of LF by annual single dose 
of DEC/Ivermectin plus Albendazole to entire eligible 
population living in area where the disease is 
endemic (area where microfilarimia or antigenemia 
is >1%). WHO recommends MDA for five years or 
more to reduce number of mf in the blood to the 
level (mf prevalence<1%) that prevents mosquito 
vectors from transmitting infection.8 In India. MDA 
was started in year 2004 and then extended to all 
endemic states in year 2006 with annual single dose 
of DEC plus Albendazole. The success of elimination 
of LF mainly depends on the desired coverage of 
population (≥65%) by MDA for five years or mf 
prevalence level is brought down to less than 01%. 
Out of 250 endemic districts, 186 districts were with 
mf rate less than 1%. Coverage of MDA in India was 
reported to be 74.93% in 2011. At national level, the 
mf rate which was 1.24% in 2004 brought down to 
0.41 % in 2010.9. The state of Bihar has highest rate 
of endemicity (>17%) followed by Kerala (15.70%) 
and Utter Pradesh (14.60%). Goa has showed the 
lowest endemicity of <1 percent.(10)  
The coverage of MDA in endemic states reported by 
several studies across India ranged from 32.7% to 
76.2%.(11,12,13) In our study population, 81.24% 
people did not receive MDA in the last five years. This 
low coverage of MDA is   either attributed to lack of 
reach of services of the programme or migration of 
people to other states (non-endemic) in search of 
work where MDA is not administered. Sukhvir Singh 
et al and Ashok Mishra et al found prevalence of mf 
in endemic states ranged from 0.93% to 8.85% with 
mf density in the range of 3.1percent to 10.6 
percent.14,15 The prevalence of mf in friendly 
neighbor country Nepal, in many studies ranged 
from 25.1 % to 5.8%.(16,17,18) The movement of 
people between Nepal and India could play role in 
persistence and transmission of the infection. 
The prevalence of mf and mf density in our study was 
2.01%. The number of mf per slide varied from 1 to 
21 with average mf density of 3.90. The mf 
prevalence in our study was much less than found in 
other studies carried out in endemic states but 
higher than national prevalence of mf (0.45%). This 
could be because this study was undertaken among 
people living in non-endemic state in limited 
geographical area. But this low prevalence of mf and 
mf density found in our study population is enough 
to sustain development of infective larvae in 
mosquito after biting these low density carriers in 
population and continue to maintain infection in the 
non-endemic states. S Sabesan, konganti Hari K Raju 
et al in their study also assessed risk of transmission 
in some districts in non-endemic states (Harayana, 
Punjab and Uttarakhand) and recommended for 
MDA after conduct of epidemiological survey.(19) 
Conclusion 
The higher endemicity (2.01%) of mf among 
migratory population than national average (0.45%) 
and the level which is capable of continuing 
transmission (>1%) in population at risk living in non-
endemic states where MDA is not administered 
under national programme would have higher 
probability to spread the infection to general 
population provided all other epidemiological and 
ecological criteria being met.  
The migration of people from endemic to non-
endemic states, uncontrolled urbanization, 
inadequate and substandard sanitary facilities and 
living conditions and population having infection in 
non-endemic states requires specific targeted 
approach to achieve national and global target of 
elimination of LF by year 2020. 
Based on the results of the study, it is recommended 
that migratory population living in groups near 
construction projects, brickklins, and industries in 
temporary settlements on out skirts or within cities 
in under developed areas located in non-endemic 
states should be covered by transmission 
assessment survey (TAS) followed by treatment. If 
the mf prevalence among these migrant populations 
found more than >1 percent, then these people 
should be administered two drugs (DEC+ 
Albendazole) on annual basis as administered under 
NVBDC programme till they stay in non-endemic 
states (4-5 years). 
Recommendation 
Migrant population from filaria endemic states 
staying in clusters in non-endemic should be 
subjected to annual transmission survey to assess 
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prevalence of microfilaria and MDA if prevalence 
found > 1%. 
Limitation of the study 
Study included migrants staying in one town of the 
State Punjab only. 
Relevance of the study 
This study has focused coverage of migrant 
population from endemic states living in non-
endemic states for filaria transmission and assess 
need of MDA for these migrants to achieve goal to 
eliminate LF as a public health problem by 2020. 
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Tables 
TABLE- 1 STATE WISE DISTRIBUTION OF MIGRANT POPULATION PARTICIPATED IN STUDY AND MF   
POSITIVE PERSON 
State Number of people examined % No of mf positive people % 
Bihar 450 41.20% 16 03.55% 
Chhattisgarh 14 01.28% 02 14.28% 
Jharkhand 14 00.37% 00 00.00% 
Haryana* 04 01.28% 00 00.00% 
MP 184 16.85% 02 01.08% 
Odisha 118 10.81% 00 00.00% 
Punjab* 20 01.83% 00 00.00% 
Rajasthan* 06 00.55% 00 00.00% 
UP 190 17.40% 02 01.05% 
WB 90 08.24% 00 00.00% 
Nepal 02 100% 00 00.00% 
Total 1092 100.00 22 02.01% 
  * Indicate non-endemic state - total person 30 (2.75%) 
TABLE 2THE AGE WISE DISTRIBUTION OF STUDY POPULATION AND MF POSITIVE PERSON 
Age in years Study population % No. of mf +ve person %   
 Male Female Total    
Below 10   20 21     41 03.75 02 04.87 
10 - 20 212 20   232 21.25 07 03.01 
21 - 30 398 84   482 44.14 10 02.07 
31 - 40 184 32   216 19.78 02 00.92 
41 - 50 106 13   119 10.90 01 00.84 
Above 50   02 00     02 00.18 00 00.00 
TABLE 3 THE TRADE WISE DISTRIBUTION OF STUDY POPULATION AND MF POSIT IVE PERSON 
Trade 
Study Population 
% No. of mf +ve persons % 
Male Female Total 
Un/Semi skilled 662 136 798 78.70 15 01.87 
Skilled 199 00 199 19.62 05 02.51 
Supervisor 17 00 17 01.68 00 00.00 
Total 878 136 1014 100.00 20 01.97 
TABLE 4 THE EDUCATION WISE DISTRIBUTION OF STUDY POPULATION AND MF POSITIVE PERSON 
TABLE 5 THE DISTRIBUTION OF PERSON RECEIVED MDA IN LAST FIVE YEARS 
Number of times MDA received Number of person received Percentage 
Once 151 13.83 
Twice 42 03.84 
Thrice or more 12 01.09 
None 887 81.24 
Total 1092 100.00 
 
Education Study population % No mf +ve  
persons 
% 
Male Female Total 
Illiterate 274 153 427  39.72  13 03.04 
Up to 5thstd 324   07 331  30.79  07 02.11 
Up to 12 std 308   00 308  28.65  01 00.32 
Diploma/Graduate   09   00   09  00.84  00 00.00 
Total 915 160 1075 100.00  21 01.95 
